Strongbridge Biopharma plc to Host Conference Call on March 12, 2018 to Announce Fourth Quarter and Year-End 2017 Financial R...
February 28 2018 - 7:30AM
Strongbridge Biopharma plc (Nasdaq:SBBP), a global commercial-stage
biopharmaceutical company focused on the development and
commercialization of therapies for rare diseases with significant
unmet needs, today announced that it will host a conference call
with members of Strongbridge’s management team on Monday, March 12
at 8:30 a.m. ET to discuss the Company’s fourth quarter and
year-end 2017 financial results and provide a corporate update. The
conference call will follow the anticipated release of the
Company’s financial results earlier that day.
Event Details Strongbridge will host a
conference call on Monday, March 12 at 8:30 a.m. ET. To access the
live call, dial 844-285-7153 (domestic) or 478-219-0180
(international) with conference ID 6497969. The conference call
will also be audio webcast from the Company’s website
at www.strongbridgebio.com under the “Investor/Webcasts
and Presentations” section. A replay of the call will be made
available for one week following the conference call. To hear a
replay of the call, dial 855-859-2056 (domestic) or 404-537-3406
(international) with conference ID 6497969.
About Strongbridge
BiopharmaStrongbridge Biopharma is a global
commercial-stage biopharmaceutical company focused on the
development and commercialization of therapies for rare diseases
with significant unmet needs. Strongbridge's commercial portfolio
within its rare neuromuscular and rare endocrine franchises
includes Keveyis® (dichlorphenamide), the first and
only FDA-approved treatment for hyperkalemic, hypokalemic, and
related variants of primary periodic paralysis, and Macrilen™
(macimorelin), the first and only FDA-approved oral drug
indicated for the diagnosis of adult growth hormone deficiency. The
Company’s rare endocrine franchise also includes a clinical-stage
pipeline of therapies: Recorlev™ (levoketoconazole), a
cortisol synthesis inhibitor currently being studied for the
treatment of endogenous Cushing's syndrome, and veldoreotide, a
next-generation somatostatin analog being investigated for the
treatment of acromegaly, with potential additional applications in
other conditions amenable to somatostatin receptor activation.
Contacts:
Corporate and Media Relations Elixir Health
Public Relations Lindsay Rocco +1 862-596-1304
lrocco@elixirhealthpr.com
Investor RelationsUnited
States:The Trout Group Marcy Nanus +1 646-378-2927
mnanus@troutgroup.com
Europe:First HouseMitra Hagen Negård+47 21 04
62 19strongbridgebio@firsthouse.no
USA 900 Northbrook Drive Suite 200 Trevose,
PA 19053 Tel. +1 610-254-9200 Fax. +1 215-355-7389
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From Jul 2023 to Jul 2024